Objective To estimate health benefits and incremental cost‐effectiveness of human
papillomavirus (HPV) vaccination of pre‐adolescent boys and girls compared with girls …

Background: Data to inform evidence-based policy of human papillomavirus (HPV) vaccine
delivery strategies in low-and middle-income countries are limited. We examined the cost …

Abstract Globally, gender-neutral Human Papillomavirus (HPV) vaccination programmes are
gaining traction. Although cervical cancer remains the most prevalent, other HPV-related …

Background Human papillomavirus (HPV) vaccines have the potential to reduce cervical
cancer incidence and mortality, particularly in the parts of the developing world that bear the …

Background Human papillomavirus (HPV) infection has been shown to be a major risk factor
for cervical cancer. Vaccines against HPV-16 and HPV-18 are highly effective in preventing …

Using mathematical models of cervical cancer for the northern and southern regions of
Vietnam, we assessed the cost-effectiveness of cervical cancer prevention strategies and …

Objective To estimate the health impact, financial costs, and cost‐effectiveness of scaling‐up
coverage of human papillomavirus (HPV) vaccination (young girls) and cervical cancer …

Introduction: Human papillomavirus (HPV) is one of the world's most common sexually
transmitted infections, and has been associated with a number of cervical and non-cervical …

Background Although guidelines for prophylactic human papillomavirus (HPV) vaccination
recommend two doses for girls ages 9–14 years, several studies have demonstrated similar …

Vaccines against the human papillomaviruses (HPV) that cause around 70% of cervical
cancer cases worldwide are highly efficacious when administered before infection with the …